22 results on '"Finetti, Pascal"'
Search Results
2. Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
3. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion
4. WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
5. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
6. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
7. Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease
8. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer
9. Difference in Therapeutic Response Between Basal and Nonbasal Triple‐Negative Breast Cancers
10. Comprehensive genome characterization of solitary fibrous tumors using high‐resolution array‐based comparative genomic hybridization
11. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
12. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
13. Genome profiling of pancreatic adenocarcinoma
14. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
15. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer
16. Gene expression profiling of inflammatory breast cancer
17. How different are luminal A and basal breast cancers?
18. Absence of ESR1 amplification in a series of breast cancers
19. How basal are triple‐negative breast cancers?
20. Moesin expression is a marker of basal breast carcinomas
21. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer.
22. The MonarchE trial: improving the clinical outcome in HR + /HER2 - early breast cancer: recent results and next steps.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.